CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

Researchers sought to identify prognostic factors for survival in patients with newly diagnosed multiple myeloma.

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Despite being the second most common haematologic cancer globally, treatment options for multiple myeloma remain limited, with a significant need for new therapies. 1 Multiple myeloma originates i ...

Looking at the genetic makeup of multiple myeloma cells can help in deciding how aggressive treatment should be and what therapy to take. A fluorescence in situ hybridization test (FISH) is one of the ...

According to Binod Dhakal of the Medical College of Wisconsin, one of the study investigators, the approval gives patients the opportunity for a treatment-free period for their multiple myeloma as ...

As a consequence of the transfer of its Jyseleca® business to Alfasigma, the revenues and costs related to Jyseleca® for the full years 2024 and 2023 are presented separately from the results of the ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Savara Inc. (NASDAQ:SVRA), that sends out a positive ...

It’s a hard day but I have faith and amazing surgeons and know everything will be ok,” she wrote on IG stories.